Abstract
Background On an initial urine screening test for illegal substances, if the concentration of a substance is at or above the determined legislative threshold, it is reported as positive. Repeat testing with the same sample to verify before reporting is a common practice of clinical laboratories. This study aimed to determine whether measurement uncertainty (MU) results can be used to detect a gray zone to reduce repeat testing.Materials and Methods
A retrospective study using data from … ….. …… ……. laboratory information system between 1.January.2020 and 1.July.2022 was conducted. The MU values for urinary amphetamine, cannabinoid, cocaine, and opioid parameters using ADVIA Chemistry reagents (Siemens Healthcare Diagnostic Inc., Germany) on a Siemens ADVIA 1800 chemical analyzer were calculated. The gray zone was defined as the cut-off value ± MU. Samples that were studied twice within one hour before reporting for the same urine sample were analyzed.
Results
From a total of 31,839 patients’ (16–65 years), urine samples, 319 amphetamine, 198 cannabinoid, 112 cocaine, and 125 opiate tests were repeated. Mean biases between the repeat test results were -7.64 (95% CI: −13.71 to -1.57) for the amphetamine and 1.16 (95% CI: 0.31 to 2.01) for the cannabinoid results. Ten amphetamine, 12 cannabinoid and 2 cocaine test results changed from positive to negative or negative to positive on retesting, all within the gray zone level defined by the MU value.
Conclusions
It is necessary to define the gray zone around the cut-off value for each illicit substance based on its MU for repeat testing.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.